A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

This study is not recruiting in the United States.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Clozapine

Criteria

Inclusion Criteria:

• Diagnosed as schizophrenia

• Not responded to at least two atypical antipshychotics launched in Japan

• Inpatient

Exclusion Criteria:

• Low white blood cell count

• Significant heart diseases

• Diabetes mellitus

Other protocol-defined exclusion criteria may apply.